Artificial Intelligence (AI) has become one of the fastest growing industries in recent years, with many companies investing heavily in developing new technologies and applications. As a result, the demand for AI stocks has skyrocketed, with investors looking to capitalize on the potential profits of this rapidly expanding sector. There are a variety of different AI stocks available on the market, each offering unique opportunities for growth and investment. Some of the most popular AI stocks include $AI, $FOXO, $GFAI, $BZFD among others. Each of these companies is engaged in different aspects of the AI industry, from machine learning and computer vision, to natural language processing and robotics. Regardless of the specific focus, AI stocks offer exciting investment opportunities for those looking to capitalize on the growth of the artificial intelligence sector.
The artificial intelligence industry is all set to grow at an impressive pace and even more so due to the innovative products which are being produced by several firms. This brings us to the subject of the latest events at ImmunoPrecise Antibodies Ltd (NASDAQ:IPA).
Back in December last year it had emerged that the company’s subsidiary unit BioStrand had been successful in indexing and encoding as many as 20 million distinct biological structures into LENS, its own artificial intelligence platform. While the development in itself was a significant one, it is perhaps important for investors to take a closer look at LENS as an artificial platform and the reason why it has been turning heads.
The encoding and indexing provided ImmunoPrecise Antibodies with the ability to perform fast antibody analysis with a computer and more importantly, it has provided the company with the capability of creating therapeutics entirely on a computer. As far as convenience is concerned, it could prove to be a game changer for the company and it had all been made possible thanks to the artificial intelligence platform LENS.
In addition to that, the algorithm that is at the center of the LENS platform continuously improves and learns new things as it continues to analyze. At this point in time, the technology that underpins the platform can manage to connect in excess of 25 billion relations and that is a staggering figure all things considered.
The fact that ImmunoPrecise Antibodies has this platform at its disposal gives it the opportunity to address one of the major challenges facing the world of science. The challenge in question is that of connecting functional biological data to protein structures or structural patterns.
In addition to that, ImmunoPrecise Antibodies believes that the technology could prove to be the link that can help researchers as well as big-ticket pharmaceutical companies across the world. At this point in time, researchers as well as some of the biggest pharmaceutical companies are not in a position to make connections between predicted protein structures and text.
Additionally, the platform can also help researchers in working out the actual function of a protein. At the end of the day, merely knowing the structures of thousands upon thousands of proteins would not be of much help if it is not possible to work out the actual functions of those.
The fact that the algorithm powering the LENS platform learns and continuously improves helps it analyse data points and then inform researchers about the actual function of the proteins in question. At this point in time, there is no other software or platform that can perform this function and that is perhaps the reason why LENS is now the talk of the town among researchers.
The breakthrough could eventually help in completely upending the pharmaceutical industry and it would be ImmunoPrecise Antibodies that would be responsible for such an eventuality. It would be interesting to see how the entire thing progresses in the coming days.